Zhejiang Xinguang Pharmaceutical Co Ltd (300519) — Tangible Net Worth Ratio
Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has a Tangible Net Worth Ratio of 99.1% as of September 2025. This metric is calculated by deducting intangible assets (CN¥7.66 Million) from net assets (CN¥827.95 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Zhejiang Xinguang Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang Xinguang Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2024)
This chart shows how Zhejiang Xinguang Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 99.1%, reflecting net assets of CN¥827.95 Million with intangible assets of CN¥7.66 Million CNY. See Zhejiang Xinguang Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 300519 company net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 99.1% | CN¥830.53 Million | CN¥7.88 Million | CN¥909.78 Million | ▲ +0.0 pp |
| 2023 | 99.0% | CN¥844.12 Million | CN¥8.17 Million | CN¥930.41 Million | ▲ +0.1 pp |
| 2022 | 98.9% | CN¥858.89 Million | CN¥9.28 Million | CN¥957.76 Million | ▲ +0.1 pp |
| 2021 | 98.8% | CN¥846.22 Million | CN¥10.41 Million | CN¥932.40 Million | ▲ +0.2 pp |
| 2020 | 98.6% | CN¥826.94 Million | CN¥11.54 Million | CN¥890.79 Million | ▲ +0.2 pp |
| 2019 | 98.4% | CN¥799.71 Million | CN¥12.68 Million | CN¥861.13 Million | ▼ -0.3 pp |
| 2018 | 98.7% | CN¥753.26 Million | CN¥9.60 Million | CN¥822.50 Million | ▲ +0.1 pp |
| 2017 | 98.6% | CN¥705.81 Million | CN¥9.83 Million | CN¥775.05 Million | ▲ +0.2 pp |
| 2016 | 98.4% | CN¥640.46 Million | CN¥10.14 Million | CN¥700.95 Million | ▲ +1.7 pp |
| 2015 | 96.7% | CN¥309.35 Million | CN¥10.24 Million | CN¥362.87 Million | ▲ +0.9 pp |
| 2014 | 95.8% | CN¥249.00 Million | CN¥10.52 Million | CN¥303.10 Million | ▲ +1.1 pp |
| 2013 | 94.6% | CN¥201.97 Million | CN¥10.81 Million | CN¥246.26 Million | ▲ +2.5 pp |
| 2012 | 92.2% | CN¥141.62 Million | CN¥11.09 Million | CN¥217.44 Million | ▲ +9.8 pp |
| 2011 | 82.4% | CN¥104.32 Million | CN¥18.40 Million | CN¥219.35 Million | — |